Functional Assessment Following Intrathecal Baclofen Therapy in Children With Spastic Cerebral Palsy

Abstract

The purpose of this article is to describe outcomes of intrathecal baclofen therapy for 29 patients with cerebral palsy, focusing on impairments, functional limitations, and disability. Patients received individualized rehabilitation and were followed up to 24 months. The primary outcome measures were the Ashworth Scale and the functional skills and caregiver assistance scales of the Pediatric Evaluation of Disability Inventory (PEDI). Ashworth Scale scores were significantly reduced (P .0005). All areas of functional skills and caregiver assistance improved. Comparing groups of adults and patients less than 18 years, there were no significant differences, but there was a relationship between age and dose. Comparing groups of patients in high and low levels of independent functional mobility, no significant differences were found. These results provide suggestive evidence that the combination of intrathecal baclofen therapy and rehabilitation has positive effects across the dimensions of disablement. This study serves as a basis for high-level scientific studies of these effects. (J Child Neurol 2003; 18: 26—34).

Get full access to this article

View all access options for this article.

References

Kroin J. , Bianchi G. , Penn R. : Intrathecal baclofen down-regulates GABA-B receptors in the rat substantia gelatinosa. J Neurosurg 1993;79:544—549.

Albright AL : Spastic cerebral palsy; approaches to drug treatment. CNS Drugs 1995;4:17—27.

National Advisory Board: Research Plan for the National Center for Medical Rehabilitation Research . NIH Publication 93-3509. US Department of Health and Human Services, Washington, DC, 1993.

Damiano DL , Quinlivan JM , Owen BF , et al: What does the Ashworth Scale really measure and are instrumented measures more valid and precise? Dev Med Child Neurol 2002; 44: 112—118.

Haley S. , Coster W. , Ludlow L. , et al: Pediatric Evaluation of Disability Inventory (PEDI): Development, Standardization and Administration Manual. Boston, PEDI Research Group, New England Medical Center Hospitals, 1992.

Feldman A. , Haley S. , Coryell J. : Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther 1990;70:602—610.

Haley S. , Coster W. , Faas R. : A content validity study of the Pediatric Evaluation of Disability Inventory. Pediatr Phys Ther 1991;3:177—184.

Campbell S. , Almeida G. , Penn R. , Corcos D. : The effects of intrathecally administered baclofen on function in patients with spasticity. Phys Ther 1995;75:352—362.

Butler C. , Campbell S. : Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. Dev Med Child Neurol 2000; 42: 634—645.

10.

Barry M. , Albright A. , Shultz B. : Intrathecal baclofen therapy and the role of the physical therapist. Pediatr Phys Ther 2000; 12: 77 —86.

11.

Dunnett C. , Tamhane A. : A step-up multiple test procedure. Theory and Methods 1992;87 (417):162-170.

12.

Gilmartin R. , Bruce D. , Storrs B. , et al: Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial. J Child Neurol 2000; 15: 71—77.

13.

Campbell S. : Therapy programs for children that last a lifetime . Phys Occup Ther Pediatr 1997;17:1—15.

14.

Lollar D (ed): Preventing Secondary Conditions Associated with Spina Bifida or Cerebral Palsy. Washington, DC, Spina Bifida Association of America, 1994 .

15.

Boyd R. , Graham H. : Objective clinical measures in the use of botulinum toxin A in the management of cerebral palsy. Dev Med Child Neurol 1999 : 6 (Suppl 4):23-26.